Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 180 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 180 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $13,140.00. Following the transaction, the insider directly owned 21,174 shares of the company’s stock, valued at approximately $1,545,702. This represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Tuesday, January 20th, Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89.
• On Tuesday, November 25th, Jonathan Zalevsky sold 1,157 shares of Nektar Therapeutics stock. The stock was sold at an average price of $54.28, for a total transaction of $62,801.96.

Nektar Therapeutics Trading Down 0.2%

Shares of NKTR traded down $0.13 during mid-day trading on Friday, reaching $73.73. The company had a trading volume of 997,867 shares, compared to its average volume of 1,533,099. Nektar Therapeutics has a fifty-two week low of $6.45 and a fifty-two week high of $74.89. The firm has a fifty day simple moving average of $45.81 and a 200-day simple moving average of $48.36. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -9.25 and a beta of 1.34.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Piper Sandler reissued an “overweight” rating and issued a $105.00 target price on shares of Nektar Therapeutics in a research note on Monday, January 26th. Citigroup assumed coverage on Nektar Therapeutics in a research report on Wednesday, November 26th. They issued a “buy” rating and a $102.00 price objective on the stock. William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 10th. Finally, HC Wainwright raised their target price on Nektar Therapeutics from $135.00 to $165.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $119.86.

Institutional Investors Weigh In On Nektar Therapeutics

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in shares of Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 210 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in Nektar Therapeutics during the 2nd quarter worth $39,000. Compass Wealth Management LLC bought a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $88,000. Bessemer Group Inc. raised its stake in shares of Nektar Therapeutics by 1,741.2% in the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,480 shares in the last quarter. Finally, Bayforest Capital Ltd bought a new position in shares of Nektar Therapeutics during the third quarter worth about $96,000. Institutional investors and hedge funds own 75.88% of the company’s stock.

Key Nektar Therapeutics News

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple multi‑quarter and full‑year EPS projections (FY2026 and FY2027 were revised to smaller losses), indicating improved analyst expectations for Nektar’s future results — a generally constructive signal for the stock. MarketBeat NKTR
• Positive Sentiment: Nektar announced research collaboration with UCSF to test a TNFR2‑agonist/antibody approach in multiple sclerosis — a meaningful pipeline development that could add long‑term value if clinical data are positive. MSNewsToday: UCSF, Nektar team BioWorld: TNFR2 agonism in MS
• Neutral Sentiment: An AAII piece compared Nektar to another biotech (Harmony Biosciences) as an investment choice — useful context for longer‑term investors but unlikely to move the stock materially on its own. AAII comparison article
• Negative Sentiment: Zacks cut near‑term quarter estimates for Q2 2026 (and separately trimmed Q2 2027), signaling some expected near‑term pressure to results that can weigh on sentiment. MarketBeat NKTR

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.